Clinical Trials Logo

Clinical Trial Summary

The purpose of this study was to evaluate the efficacy and safety of Camrelizumab as maintenance therapy in newly diagnosed locally advanced head and neck squamous cell carcinoma subjects after chemoradiation.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04861467
Study type Interventional
Source Chinese Academy of Medical Sciences
Contact Junlin Yi
Phone 13661217998
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date June 1, 2021
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02999087 - Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) Phase 3
Recruiting NCT03292250 - Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)] Phase 2
Recruiting NCT04606940 - Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)
Recruiting NCT03356587 - A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy Phase 2
Recruiting NCT03719690 - Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy Phase 2
Active, not recruiting NCT03367780 - Dose-Effect Relation of Salivary Gland Irradiation
Recruiting NCT04042935 - Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC Phase 1
Recruiting NCT04157985 - Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors Phase 3
Recruiting NCT04279509 - Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE) N/A
Recruiting NCT03652142 - Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma
Recruiting NCT03082534 - Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT04169074 - Modulation of the Tumor Microenvironment by Abemaciclib in Operable HPV-Negative Head and Neck Cancer (HNC) Phase 2
Active, not recruiting NCT03107182 - Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer Phase 2
Not yet recruiting NCT04831450 - Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) Phase 2
Not yet recruiting NCT04811027 - Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC Phase 2
Recruiting NCT03726775 - Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN Phase 2
Completed NCT03740100 - Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations Phase 2
Recruiting NCT04722523 - A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer Phase 1
Not yet recruiting NCT04141449 - A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation Phase 2
Recruiting NCT02998385 - Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy) Phase 3